Dr John Campbell
@campbellteaching·3.3M subscribers·3.1K videos
New antiviral drug in trials
Posted
March 27, 2021
Views
121,882
Likes
4,327
Comments
1,912
Engagement
5.12%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
YouTube Description
as posted by the channelNovel oral antiviral for SARS-CoV-2 progresses in Phase I trial, Protease inhibitor
Background science
Viral proteases are enzymes, endopeptidases
Encoded by the genetic material (DNA or RNA) of viral pathogens
Catalyze cleavage of specific peptide bonds in viral precursors
These proteolytic events are essential for the completion of the viral infectious cycle
Protease inhibitors, bind to a viral enzyme, called a protease
Prevent the virus from replicating
Protease inhibitors, used to treat HIV and hepatitis C
Assess tolerability and safety of multiple ascending doses of PF-07321332
Phase I study, healthy adults
Randomised, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study in healthy adults evaluating the safety, tolerability and pharmacokinetics of PF-07321332.
Protease inhibitor, demonstrated potent in vitro antiviral activity against SARS-CoV-2 and other coronaviruses.
Could be prescribed orally at the first sign of infection
Pfizer also investigating an intravenously administered protease inhibitor, PF-07304814, in hospitalised patients with COVID-19.
November??
Links & Promotions
Guests & Subjects Covered
Phase IC AssessPF- Phase IPF- ProteaseCOVID- November
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.